EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY 4.0

Safety and Efficacy Findings From a Phase Ib/ II Study of ASP ‐1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

David M Cognetti, Joseph M Curry, Jennifer Johnson, Michael Kwon, Shirley Y Su, Francisco Civantos, Coral Olazagasti, Joseph Valentino, Susanne M Arnold, R Bryan Bell, Michael K Gibson, Kyle Mannion und 6 weitere

Head & Neck · 2026-01 · 48 (1) · 160-174

DOI: 10.1002/hed.70014 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Head & Neck, online erschienen am 25.08.2025. Verfasst von David M Cognetti und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology - Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Neoplasm Recurrence, Local, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Rakuten Medical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ASP‐1929 photoimmunotherapy—cetuximab conjugated to IRDye 700DX and red light (690 nm) for localized drug activation—results in rapid, selective cell killing.

Methods

This phase Ib/II open‐label study evaluated ASP‐1929 photoimmunotherapy plus pembrolizumab in patients with recurrent/metastatic HNSCC (≥ 1 accessible lesion, PD‐L1 combined positive score ≥ 1, ineligible for standard locoregional therapy). Primary objectives were safety/tolerability and objective response rate (ORR). Secondary objectives included overall survival (OS) and progression‐free survival (PFS).

Results

Eighteen patients (median age 63 years, 74% male) comprised the photoimmunotherapy‐evaluable population. The confirmed ORR was 27.8% (95% CI 9.7–53.5); four of five responders had complete responses (95% CI, 6.4–47.6). Median OS was 25.6 months (95% CI, 14.6–not evaluable); median PFS was 2.9 months (95% CI, 1.4–14.6). The most common serious adverse reactions were dysphagia and tongue edema (each n = 2; 10.5%).

Conclusions

ASP‐1929 photoimmunotherapy plus pembrolizumab was generally tolerable, with promising efficacy in patients with recurrent/metastatic HNSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedNeoplasm Recurrence, LocalSquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsCetuximabImmunotherapyAntineoplastic Agents, ImmunologicalPhototherapyHumansMaleMiddle AgedFemaleAgedTreatment OutcomeAdultProgression-Free Survival

Stichwörter der Autor:innen

ASP‐1929 photoimmunotherapyHNSCCadvanced diseasebiomarker analysispembrolizumab

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabCetuximabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Otolaryngology - Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Department of Diagnostic Radiology, Division of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Otolaryngology - Head and Neck Surgery, Miller School of Medicine, University of Miami, Miami, Florida, USA.

Förderung

  • NCI NIH HHS
  • Rakuten Medical

Zitieren

APA

Cognetti, D. M., Curry, J. M., Johnson, J., Kwon, M., Su, S. Y., Civantos, F., Olazagasti, C., Valentino, J., Arnold, S. M., Bell, R. B., Gibson, M. K., Mannion, K., Van Abel, K. M., Price, K. A., Dong, H., Thorne, A. H., Suzuki, T., & Gillenwater, A. M. (2026). Safety and Efficacy Findings From a Phase Ib/ II Study of ASP ‐1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Head & Neck, 48(1), 160-174. https://doi.org/10.1002/hed.70014

Vancouver

Cognetti DM, Curry JM, Johnson J, Kwon M, Su SY, Civantos F, et al. Safety and Efficacy Findings From a Phase Ib/ II Study of ASP ‐1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Head & Neck. 2026;48(1):160-174. doi:10.1002/hed.70014

BibTeX
@article{Cognetti2026,
  author = {Cognetti, David M and Curry, Joseph M and Johnson, Jennifer and Kwon, Michael and Su, Shirley Y and Civantos, Francisco and Olazagasti, Coral and Valentino, Joseph and Arnold, Susanne M and Bell, R Bryan and Gibson, Michael K and Mannion, Kyle and Van Abel, Kathryn M and Price, Katharine A and Dong, Haiying and Thorne, Amy H and Suzuki, Toshiaki and Gillenwater, Ann M},
  title = {Safety and Efficacy Findings From a Phase Ib/ II Study of ASP ‐1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma},
  journal = {Head & Neck},
  year = {2026},
  volume = {48},
  number = {1},
  pages = {160--174},
  doi = {10.1002/hed.70014}
}
Kostenlos starten →